Cohort Study on Prognosis of Patients with Metastatic Colorectal Cancer Treated with Integrated Chinese and Western Medicine

作     者：ZHANG Tong HE Wen-ting ZI Ming-jie SONG Gang YI Dan-hui YANG Yu-fei 

作者机构：Department of OncologyXiyuan Hospital of China Academy of Chinese Medical Sciences Second Department of OncologyTraditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University Ethics CommitteeXiyuan Hospital of China Academy of Chinese Medical Sciences Department of Digestive OncologyBeijing Cancer Hospital School of StatisticsRenmin University of China 

出 版 物：《Chinese Journal of Integrative Medicine》 (中国结合医学杂志（英文版）)

年 卷 期：2018年第24卷第8期

页      面：573-578页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by National Natural Science Foundation of China(No.81373824) Beijing Health Development Research Project(No.2016-1-4147) Project of the Chinese Academy of Traditional Chinese Medicine(No.ZZ070854) 

主　　题：cohort study metastatic colorectal cancer integrative medicine 

摘      要：Objective： To investigate the efficacy of integrated Chinese and Western medicine（IM） in the treatment of metastatic colorectal cancer（m CRC） in a cohort ***： The survival outcome of patients receiving IM was compared with that of patients receiving Western medicine *** study design was adopted with ＂continuous administration of Chinese medicine for 3 months＂ as the exposure *** who met this exposure factor were assigned to the IM cohort（Group A,110 patients）.Patients who did not meet this exposure factor were assigned to the Western medicine cohort（Group B,225 patients）.The overall survival（OS）,progression-free survival（PFS）,and 1 st year,2 nd year,and 3 rd year survival in the two cohorts were ***： The median OS in Group A and B were 18 months [95% confidence interval（CI） 15-21] and 16 months（95% CI 14-18）,respectively,and the median PFS in Group A and B were 6 months（95% CI 4-7） and 5 months（95% CI 4-6）,*** statistically significant differences were observed between the groups（P=0.186,P=0.223）.Group A demonstrated significantly longer OS and PFS than Group B in the following subgroups： female patients,patients with lesions in the right half of the colon,and those who received first-line treatment（P〈0.05）.In the subgroup of elderly patients（age〉65 years）,the OS in Group A was longer than that in Group B（P〈0.05）.Conclusion： IM could prolong the survival of patients with m CRC.（Registry *** CTR-IOR-17010497）